BRIEF published on 04/28/2026 at 20:40, 16 days 20 hours ago GenSight Biologics announces its 2026 Combined General Meeting Shareholders Gene Therapy General Assembly Preparatory Documents GenSight Biologics
BRIEF published on 04/28/2026 at 20:40, 16 days 20 hours ago GenSight Biologics Schedules Annual General Meeting for May 2026 Annual General Meeting Regulatory Compliance Shareholder Information Investor Relations Gene Therapy
PRESS RELEASE published on 04/28/2026 at 20:35, 16 days 20 hours ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 19, 2026, in Paris. Shareholders can access preparatory documents online. Meeting details and documents available on company website Annual General Meeting Shareholders Preparatory Documents Meeting Details GenSight Biologics
BRIEF published on 04/07/2026 at 19:04, 1 month 7 days ago GenSight Biologics Reports Cash Status and Early Access Revenues Revenue Cash Position Gene Therapy GenSight Biologics Early Access Program
BRIEF published on 04/07/2026 at 19:04, 1 month 7 days ago GenSight Biologics: Financial Update and Progress on AAC Fundraising Treasury Gene Therapy GenSight Biologics Compassionate Access
PRESS RELEASE published on 04/07/2026 at 18:59, 1 month 7 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and revenue from early access program as of March 31, 2026. Operating cash burn, fundraising, and treatment proceeds highlighted Revenue Fundraising Cash Position GenSight Biologics Early Access Program
BRIEF published on 03/27/2026 at 07:35, 1 month 19 days ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
PRESS RELEASE published on 03/27/2026 at 07:30, 1 month 19 days ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 1 month 23 days ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
BRIEF published on 03/18/2026 at 10:20, 1 month 28 days ago GenSight Biologics finalizes its €1.7 million fundraising round Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
Published on 05/15/2026 at 14:35, 2 hours 48 minutes ago NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
Published on 05/15/2026 at 14:30, 2 hours 53 minutes ago AIAI Holdings Corporation Expresses Appreciation to Revere Securities for Financial Advisory Support on Successful NASDAQ Direct Listing
Published on 05/15/2026 at 14:00, 3 hours 23 minutes ago CCL Industries Announces 2026 Annual and Special Shareholders' Meeting Results
Published on 05/15/2026 at 14:00, 3 hours 23 minutes ago First Canadian Graphite to Attend the Mining Investment Event in Quebec City
Published on 05/15/2026 at 14:00, 3 hours 23 minutes ago Underground Gold Potential Grows at Colosseum
Published on 05/15/2026 at 16:48, 35 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/15/2026 at 15:35, 1 hour 48 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 05/15/2026 at 15:34, 1 hour 49 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 05/15/2026 at 15:33, 1 hour 50 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 05/15/2026 at 15:08, 2 hours 15 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/13/2026 at 17:45, 1 day 23 hours ago Infotel confirms its return to growth in Q1 2026 with revenue up 8.6%. Proposed dividend of €2 per share for 2025.
Published on 05/13/2026 at 17:45, 1 day 23 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2026
Published on 05/13/2026 at 17:40, 1 day 23 hours ago Report on share repurchases from 6 to 12 May 2026
